Premenstrual Dysphoric Disorder.

Teresa Lanza di Scalea, Teri Pearlstein

Journal: The Medical clinics of North America 2019;103(4):613-628

PMID: 31078196

Full Text on Elsevier Science View on PubMed

Abstract

Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

Address: Assistant Professor of Psychiatry and Women's Health, Dell Medical School, University of Texas at Austin, Austin, TX, USA. Electronic address: [email protected].; Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Women's Behavioral Medicine, Women's Medicine Collaborative, Miriam Hospital, 146 West River Street, Providence, RI 02904, USA.

DOI: 10.1016/j.mcna.2019.02.007

Link outs

Free resources

Medical:

https://medlineplus.gov/premenstrualsyndrome.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Contraceptives, Oral, Contraceptives, Oral, Hormonal, Female, Humans, Premenstrual Dysphoric Disorder, Premenstrual Syndrome, Selective Serotonin Reuptake Inhibitors, Women's Health